Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | $0.00 | $0.00 | $20.0K | $0.00 | $0.00 | $27.6K | $157K |
| Revenue growth | — | — | — | — | — | — | -100.0% | — | — | 468.6% |
| Gross profit | — | — | — | — | — | — | — | $0.00 | $11.6K | $49.0K |
| Gross margin | — | — | — | — | — | — | — | — | 42.0% | 31.1% |
| Operating income | -$3.06M | -$3.49M | -$6.33M | -$6.13M | -$8.35M | -$8.56M | -$8.65M | -$8.73M | -$7.26M | -$13.4M |
| Operating margin | — | — | — | — | — | -42778.4% | — | — | -26267.7% | -8498.9% |
| Net income | -$5.79M | -$6.06M | -$10.0M | -$14.6M | -$11.5M | -$9.11M | -$8.76M | -$8.75M | -$7.78M | -$13.4M |
| Net margin | — | — | — | — | — | -45528.6% | — | — | -28127.2% | -8513.4% |
| EPS (diluted) | -$0.04 | -$0.05 | -$0.07 | -$0.09 | -$0.04 | -$0.02 | — | — | -$4.60 | -$4.23 |
| Fiscal year | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.30M | -$2.54M | -$4.24M | -$5.01M | -$3.71M | -$2.59M | -$6.80M | -$7.10M | -$5.80M | -$4.31M |
| Fiscal year | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $16.6K | $507K | $317K | $389K | $346K | $138K | $8.90M | $1.80M | $274K | $1.54M |
| Total assets | $72.7K | $737K | $332K | $412K | $369K | $220K | $8.99M | $2.12M | $556K | $1.64M |
| Total liabilities | $9.57M | $14.4M | $16.6M | $22.7M | $8.71M | $11.5M | $2.95M | $2.13M | $2.76M | $2.16M |
| Shareholders' equity | -$9.50M | -$13.6M | -$16.3M | -$22.3M | -$8.34M | -$11.3M | $6.04M | -$10.6K | -$2.21M | -$515K |
| Retained earnings | -$47.7M | -$53.8M | -$63.8M | -$78.4M | -$90.0M | -$99.1M | -$107M | -$116M | -$124M | -$137M |
| Shares (wtd avg diluted) | 132M | 137M | 141M | 180M | 413M | 5.16M | 9.42M | 1.57M | 1.69M | 3.17M |
Every figure is extracted from Zivo Bioscience, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.